Frontline management of epithelial ovarian cancer—combining clinical expertise with community practice collaboration and cutting-edge research

Edward Wenge Wang, Christina Hsiao Wei, Sariah Liu, Stephen Jaejin Lee, Susan Shehayeb, Scott Glaser, Richard Li, Siamak Saadat, James Shen, Thanh Dellinger, Ernest Soyoung Han, Daphne Stewart, Sharon Wilczynski, Mihaela Cristea, Lorna Rodriguez-Rodriguez

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Epithelial ovarian cancer (EOC) is the most common histology of ovarian cancer defined as epithelial cancer derived from the ovaries, fallopian tubes, or primary peritoneum. It is the fifth most common cause of cancer-related death in women in the United States. Because of a lack of effective screening and non-specific symptoms, EOC is typically diagnosed at an advanced stage (FIGO stage III or IV) and approximately one third of patients have malignant ascites at initial presentation. The treatment of ovarian cancer consists of a combination of cytoreductive surgery and systemic chemotherapy. Despite the advances with new cytotoxic and targeted therapies, the five-year survival rate for all-stage EOC in the United States is 48.6%. Delivery of up-to-date guideline care and multidisciplinary team efforts are important drivers of overall survival. In this paper, we review our frontline management of EOC that relies on a multi-disciplinary approach drawing on clinical expertise and collaboration combined with community practice and cutting edge clinical and translational research. By optimizing partnerships through team medicine and clinical research, we combine our cancer center clinical expertise, community practice partnership, and clinical and translational research to understand the biology of this deadly disease, advance therapy and connect our patients with the optimal treatment that offers the best possible outcomes.

Original languageEnglish (US)
Article number2830
Pages (from-to)1-16
Number of pages16
JournalJournal of Clinical Medicine
Issue number9
StatePublished - Sep 2020

All Science Journal Classification (ASJC) codes

  • Medicine(all)


  • BRCA mutation
  • Clinical research
  • Epithelial ovarian cancer
  • Frontline treatment
  • Genetics counseling
  • HRD
  • Maintenance therapy
  • PARP inhibitor
  • PIPAC adjuvant chemotherapy
  • Surgical debulking
  • Team medicine


Dive into the research topics of 'Frontline management of epithelial ovarian cancer—combining clinical expertise with community practice collaboration and cutting-edge research'. Together they form a unique fingerprint.

Cite this